A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder (MDD)

In brief

The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.

Key facts

Study ID
NCT00448292
Run by
Epix Pharmaceuticals, Inc.
People needed
330
Starts
2007-03-01
Expected to finish
2007-11-01
Last updated by the study team
2007-11-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.